Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 73Gastrointestinal 4Head & Neck 2Genitourinary 2Dermatologic 2Breast 2

Conditions

Breast Neoplasms 47Triple Negative Breast Neoplasms 25Ovarian Neoplasms 8Neoplasm Metastasis 8Melanoma 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Pancreatic Neoplasms 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Urinary Bladder Neoplasms 3Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Carcinoma, Merkel Cell 3Lung Neoplasms 2Kidney Neoplasms 2Hodgkin Disease 2Fallopian Tube Neoplasms 2Esophageal Squamous Cell Carcinoma 2Esophageal Neoplasms 2Endometrial Neoplasms 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Anatomic Stage II Breast Cancer AJCC v8 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Thyroid Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 17Docetaxel 13Specimen Handling 12Radiotherapy 11Surveys and Questionnaires 10Cyclophosphamide 10Blood Specimen Collection 9Radiosurgery 8Paclitaxel 8Gemcitabine 8Drug Therapy 8sargramostim 7Trastuzumab 7Nivolumab 7Carboplatin 7Injections 6Early Intervention, Educational 6Taxes 5Psychiatric Rehabilitation 5Methods 5Interviews as Topic 5Educational Status 5spartalizumab 4motexafin gadolinium 4aldesleukin 4X-Rays 4Therapeutics 4Standard of Care 4Spinal Puncture 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lung Neoplasms × durvalumab × Breast × Clear all
NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
58 enrolled
BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT02403271 2019-01-03

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors

Pharmacyclics LLC.

Phase 1/2 Completed
124 enrolled 17 charts
BreastGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡